Skip to content
Panacea Biotec logo

Panacea Biotec

PANACEABIO NSE
₹344.80 +10.05 (+3.00%)
P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹344.80 −65.20 −15.9% 1Y
Start ₹410.00

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
−2.43%
Debt to Equity
0.03
EPS (TTM)
−₹1.16
Book Value
₹132.76
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
2.60
ROE
−2.42%
Dividend Yield
0.00%
EBITDA
₹12.20 Cr
52W High
₹647.00
52W Low
₹292.40
Day Range
₹330.00 – ₹351.25
Volume
64,092

Peer Comparison

Healthcare › Pharmaceuticals

Panacea Biotec peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Panacea Biotec (this company)
₹344.80—₹2,056 Cr2.600.00%−2.42%−2.43%₹673 Cr−₹9 Cr
Median 8 companies₹1,587.7038.81₹1,25,337 Cr4.570.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

44 Weak

Data confidence 91/100

Category scores

Quality
34
Poor
Returns, margins, earnings quality 22% weight
Valuation
32
Poor
Cheap vs sector & own history 24% weight
Growth
36
Poor
Sales & profit trajectory 9% weight
Financial Health
42
Weak
Solvency, leverage, coverage 9% weight
Momentum
23
Poor
Trend strength, vol-adjusted 12% weight
Ownership
76
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

6
  • Stock is trading at 2.54 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 0.47% over past five years.
  • Company has a low return on equity of -3.57% over last 3 years.
  • Earnings include an other income of Rs.26.4 Cr.
  • Company's cost of borrowing seems high

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish856
OscillatorsNeutral252
Moving AveragesStrong Bearish604

Key readings

RSI (14)
50.20
Neutral
MACD (12,26,9)
−10.87
Bullish
SMA (50)
363.60
Bearish
SMA (200)
398.46
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y−0.20%
5Y+0.48%
3Y+11.64%
1Y+14.49%
TTM+10.26%

Net profit

Net profit growth by window
10YLoss narrowed by ₹14 Cr
5YLoss narrowed by ₹141 Cr
3YLoss narrowed by ₹27 Cr
1YLoss narrowed by ₹2 Cr
TTMTurned to loss

Operating cash flow

Operating cash flow growth by window
10Y−15.44%
5Y−30.78%
3YTurned positive
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−17.93 pp
5Y−13.10 pp
3Y+20.52 pp
1Y+3.69 pp
TTM+2.48 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹544 Cr
Mar 2018₹593 Cr
Mar 2019₹457 Cr
Mar 2020₹544 Cr
Mar 2021₹625 Cr
Mar 2022₹661 Cr
Mar 2023₹460 Cr
Mar 2024₹559 Cr
Mar 2025₹559 Cr
Mar 2026₹640 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017−₹56.00 Cr
Mar 2018−₹76.00 Cr
Mar 2019₹38.00 Cr
Mar 2020−₹194 Cr
Mar 2021−₹148 Cr
Mar 2022₹1,078 Cr
Mar 2023−₹34.00 Cr
Mar 2024−₹2.00 Cr
Mar 2025−₹9.00 Cr
Mar 2026−₹7.00 Cr

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Panacea Biotec Ltd is a healthcare company with a market cap of Rs.3,437 Cr that remains loss-making with a negative PE of -469.7x and negative 3-year average ROE of -3%. While the stock has delivered a strong 63% CAGR over 3 years and TTM profit growth of 52%, the underlying business has posted near-zero sales growth over 5 and 10 years.

Bull Case 7
  • Stock has delivered a 3-year CAGR of 63%, significantly outperforming broader markets
  • TTM compounded profit growth of 52% indicates a sharp recent improvement in earnings trajectory
  • Company is almost debt free, reducing balance sheet risk and interest burden
  • 3-year compounded profit growth of 21% shows a sustained recovery trend in profitability
  • TTM sales growth of 14% marks a notable acceleration after years of stagnant revenue
  • 10-year stock CAGR of 16% shows long-term wealth creation despite operational challenges
  • 5-year compounded profit growth of 13% suggests the turnaround has been building over multiple years
Bear Case 8
  • Negative PE ratio of -469.7x indicates the company is still loss-making at the net level
  • 3-year average ROE of -3% and last year ROE of -2% show persistent inability to generate returns on equity
  • 5-year compounded sales growth of just 0.47% reflects near-complete revenue stagnation over a long period
  • Stock trades at 4.03x book value despite negative earnings, suggesting stretched valuations relative to fundamentals
  • Other income of Rs.36.4 Cr inflates reported earnings, masking weak core operating performance
  • Zero dividend yield means shareholders receive no income return while bearing equity risk
  • Company has low interest coverage ratio despite being nearly debt free, indicating weak operating profits
  • High cost of borrowing suggests lenders perceive elevated credit risk in the business

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Panacea Biotec is riding strong momentum from its EU-funded DENSTAR dengue vaccine project, which drove a 60% rally in six sessions to 52-week highs. The DengiAll platform offers genuine first-mover advantages in underserved tropical markets with its single-dose, no-blood-test design. However, the sharp 9.99% correction on Jun 10 after such a parabolic move, combined with widening standalone losses and going concern flags, suggests high volatility ahead. The trend is improving on the vaccine pipeline narrative, but execution risk remains elevated given the company's weak financials and the four-year timeline to African licensure.

Headwinds 3
  • Stock crashes 9.99% on heavy volume Jun 10

    Panacea Biotec fell 9.99% to ₹547.65 on Jun 10 with 1.52 lakh shares traded, double the monthly average of 75,434 shares, leading BSE 'B' group losers.

  • Widening losses and going concern risk Jun 9

    FY26 standalone losses widened to ₹28.74 crore from ₹15.18 crore YoY, with negative retained earnings of ₹217.82 crore raising going concern uncertainty.

  • Stock still 70% below 2021 highs Jun 9

    Despite the recent rally, the stock had fallen almost 70% from its 2021 levels before the recent recovery, indicating long-term underperformance.

Positives 5
  • DENSTAR dengue vaccine project launched Jun 8

    Panacea Biotec launched the EU-funded €11.1 million DENSTAR project on Jun 1, 2026 to fast-track DengiAll licensure across 54 African nations with a 10-partner consortium from 9 countries.

  • Stock surges 60% in six sessions Jun 9

    Shares surged 60% in six trading days from ₹398.45 on Jun 1 to a 52-week high of ₹637.70, with trading volumes jumping over five-fold and 9.95 million shares (16% of equity) changing hands.

  • DengiAll single-dose vaccine advantages Jun 9

    DengiAll requires no prior blood testing, is a single-dose cost-efficient tetravalent vaccine targeting all four dengue serotypes, making it scalable for mass rollout in low- and middle-income nations.

Neutral 1
  • DENSTAR consortium structure detailed Jun 8

    The four-year DENSTAR project is coordinated by Italy's Sclavo Vaccines Association and includes Johns Hopkins, NIAID, and research organizations in Ghana, Gabon, Mozambique, and DRC, with Phase I/III trials planned in African adults and children.

Quarterly Results

₹ Cr
PANACEABIO quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
129
143
151
136
116
147
163
133
167
141
165
167
200
Expenses
140
147
151
143
130
140
156
159
168
159
153
164
194
Operating Profit
−10.31
−3.56
−0.15
−6.04
−13.99
7
7.96
−26.88
−1.18
−17.79
11.74
2.57
5.67
OPM %
−7.98%
−2.49%
−0.1%
−4.43%
−12.09%
4.75%
4.87%
−20.28%
−0.71%
−12.61%
7.11%
1.54%
2.84%
Other Income
33.82
6
8.46
13.55
6.54
7.42
6.39
36.3
16.99
9.1
5.05
5.26
6.98
Interest
1
0.91
0.85
0.82
0.87
0.98
0.99
1.04
0.86
2.14
1.85
1.2
1.18
Depreciation
9.48
9.31
9.11
8.81
8.73
8.68
8.98
8.42
8.39
8.34
8.45
7.88
7.9
PBT
13.03
−7.78
−1.65
−2.12
−17.05
4.76
4.38
−0.04
6.56
−19.17
6.49
−1.25
3.57
Tax %
15.73%
6.56%
33.33%
−6.13%
−6.86%
1.05%
−1.37%
4875%
39.63%
−26.92%
40.06%
−20%
38.38%
Net Profit
10.98
−8.29
−2.2
−1.99
−15.88
4.71
4.44
−1.99
3.96
−14.01
3.89
−1
2.2
EPS (₹)
1.79
−1.35
−0.37
−0.32
−2.58
0.78
0.74
−0.31
0.66
−2.27
0.65
0.08
0.38

Profit & Loss

₹ Cr
PANACEABIO profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
687
653
544
593
457
544
625
661
460
559
559
640
673
Expenses
643
541
505
509
591
484
548
674
558
579
584
644
670
Operating Profit
44
112
39
84
−134
60
77
−13
−98
−20
−25
−5
2
OPM %
6%
17%
7%
14%
−29%
11%
12%
−2%
−21%
−3.5%
−4.4%
−0.7%
0.3%
Other Income
28
70
62
8
338
−21
9
1,687
154
62
55
36
26
Interest
105
127
101
101
105
174
185
181
4
4
4
6
6
Depreciation
67
73
68
57
54
43
46
44
39
37
35
33
33
PBT
−99
−19
−67
−66
45
−178
−146
1,449
13
1
−8
−7
−10
Tax %
3%
10%
−16%
15%
17%
9%
1%
26%
363%
201%
10%
−3%
—
Net Profit
−108
−21
−56
−76
38
−194
−148
1,078
−34
−2
−9
−7
−9
EPS (₹)
−17.38
−2.98
−8.89
−12.07
6.15
−31.69
−24.09
176
−5.42
−0.19
−1.37
−0.88
−1.16
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
PANACEABIO balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6
6
6
6
6
6
6
6
6
6
6
6
Reserves
449
426
350
303
344
193
−235
871
837
836
829
829
Borrowings
1,111
1,105
994
941
646
742
820
34
20
21
22
24
Other Liabilities
364
317
440
349
379
449
587
848
407
378
433
404
Total Liabilities
1,930
1,854
1,789
1,598
1,376
1,390
1,178
1,759
1,271
1,241
1,290
1,262
Fixed Assets
1,144
1,071
1,001
949
806
657
609
622
600
582
567
576
CWIP
155
161
30
40
23
24
34
17
42
102
128
144
Investments
15
9
7
7
5
6
0
5
13
40
3
10
Other Assets
616
614
750
602
542
703
534
1,114
615
517
592
532
Total Assets
1,930
1,854
1,789
1,598
1,376
1,390
1,178
1,759
1,271
1,241
1,290
1,262

Cash Flow

₹ Cr
PANACEABIO cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
37
91
131
118
105
−30
107
−108
−422
0
−27
17
Investing
−37
16
−26
55
−6
−35
−48
1,283
430
10
65
−40
Financing
−1
−117
−107
−164
−101
91
−47
−1,176
−18
−3
−3
−1
Net Cash Flow
−1
−10
−2
9
−2
26
12
−2
−10
7
35
−25
Free Cash Flow
30
85
107
103
100
−21
89
−119
−424
−71
−77
−37
CFO/EBITDA
96
64
320
146
−77
−36
141
−2,235
429
−12
108
−511

Ratios

PANACEABIO financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
52
79
95
84
71
46
49
45
48
37
47
42
Inventory Days
404
516
770
651
173
344
311
296
292
282
391
251
Days Payable
272
318
607
540
572
463
440
327
256
244
413
247
Cash Conversion Cycle
184
278
259
195
−328
−73
−80
14
83
76
25
46
Working Capital Days
−126
27
−46
−96
−363
93
−43
−229
−5
−2
65
51
ROCE %
0%
4%
2%
3%
−16%
5%
5%
−6%
−10%
−4%
−5%
−2%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Panacea Biotec insights

71 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 72.48%
  • Public 15.69%
  • Others 6.61%
  • FIIs 2.75%
  • DIIs 2.47%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Concall · Aug 2021
    PPT
  • Concall · Jul 2021
    PPT

Frequently Asked Questions about Panacea Biotec

What does Panacea Biotec Ltd do?
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company
Where is Panacea Biotec Ltd (PANACEABIO) listed?
Panacea Biotec Ltd trades as PANACEABIO on the NSE and under code 531349 on the BSE.
Which sector does Panacea Biotec Ltd belong to?
Panacea Biotec Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Panacea Biotec Ltd?
Over the last 52 weeks Panacea Biotec Ltd has traded between ₹292.4 and ₹647 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Panacea Biotec Ltd?
Panacea Biotec Ltd reported a return on equity of -2.42%. Its debt-to-equity ratio is 0.03.

Company Information

Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company

Website panaceabiotec.com
CEO Dr. Rajesh Jain Ph.D.
Employees 2,149
Listed 17 Apr 1996
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PANACEABIO.md for Panacea Biotec Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month